Sepsis Clinical Trials

Find Sepsis Clinical Trials Near You

MIRSEP - MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Septic shock:

• New onset (\<24h) of septic shock diagnosis according to Sepsis-3 definition

• (suspected) infection

• Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)

• Serum lactate level \> 2mmol/L

• Minimum age of 18 years

• Expected length of stay \>48h

• Written consent from an independent physician

⁃ Critically ill:

• Patients on mechanical ventilation (MV) in the ICU without an admission diagnosis of sepsis/septic shock according to Sepsis-3 definition

• Minimum age of 18 years

• Expected length of stay \>48h

• Written consent from an independent physician

Locations
Other Locations
Switzerland
Inselspital
RECRUITING
Bern
Time Frame
Start Date: 2026-06-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 56
Treatments
Septic shock
Patients in ICU with diagnosed septic shock
Critically ill patients
Critically ill patients in ICU without sepsis diagnosis
Related Therapeutic Areas
Sponsors
Leads: Insel Gruppe AG, University Hospital Bern

This content was sourced from clinicaltrials.gov